| General Information | |
|---|---|
| ZINC ID | ZINC000049047230 |
| Molecular Weight (Da) | 449 |
| SMILES | CC1(C)C[C@](C)(O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2O1 |
| Molecular Formula | C23Cl3N1O2 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 118.068 |
| HBA | 3 |
| HBD | 1 |
| Rotatable Bonds | 2 |
| Heavy Atoms | 29 |
| LogP | 6.756 |
| Activity (Ki) in nM | 2951.209 |
| Polar Surface Area (PSA) | 42.35 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | - |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.989 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 18 |
| Fraction csp3 | 0.26 |
| Ilogp | 4.02 |
| Xlogp3 | 6.41 |
| Wlogp | 7.04 |
| Mlogp | 5.11 |
| Silicos-it log p | 7.32 |
| Consensus log p | 5.98 |
| Esol log s | -6.99 |
| Esol solubility (mg/ml) | 0.0000461 |
| Esol solubility (mol/l) | 0.0000001 |
| Esol class | Poorly sol |
| Ali log s | -7.09 |
| Ali solubility (mg/ml) | 0.0000363 |
| Ali solubility (mol/l) | 8.09E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.92 |
| Silicos-it solubility (mg/ml) | 5.42E-08 |
| Silicos-it solubility (mol/l) | 1.21E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.49 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.99 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -7.115 |
| Logd | 4.474 |
| Logp | 6.828 |
| F (20%) | 0.002 |
| F (30%) | 0.014 |
| Mdck | 8.98E-06 |
| Ppb | 1.0095 |
| Vdss | 1.033 |
| Fu | 0.0088 |
| Cyp1a2-inh | 0.638 |
| Cyp1a2-sub | 0.35 |
| Cyp2c19-inh | 0.756 |
| Cyp2c19-sub | 0.077 |
| Cl | 6.249 |
| T12 | 0.019 |
| H-ht | 0.502 |
| Dili | 0.924 |
| Roa | 0.196 |
| Fdamdd | 0.894 |
| Skinsen | 0.017 |
| Ec | 0.003 |
| Ei | 0.01 |
| Respiratory | 0.012 |
| Bcf | 4.257 |
| Igc50 | 5.186 |
| Lc50 | 7.135 |
| Lc50dm | 6.465 |
| Nr-ar | 0.089 |
| Nr-ar-lbd | 0.508 |
| Nr-ahr | 0.672 |
| Nr-aromatase | 0.882 |
| Nr-er | 0.697 |
| Nr-er-lbd | 0.898 |
| Nr-ppar-gamma | 0.369 |
| Sr-are | 0.903 |
| Sr-atad5 | 0.248 |
| Sr-hse | 0.502 |
| Sr-mmp | 0.966 |
| Sr-p53 | 0.898 |
| Vol | 422.621 |
| Dense | 1.058 |
| Flex | 0.087 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 1 |
| Toxicophores | 0 |
| Qed | 0.453 |
| Synth | 3.187 |
| Fsp3 | 0.261 |
| Mce-18 | 86.586 |
| Natural product-likeness | -0.114 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 1 |
| Gsk | Rejected |
| Goldentriangle | Accepted |